

Valeri et al

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Extracellular Matrix Abnormalities in the Hippocampus of Subjects with Substance Use Disorder

Jake Valeri^{a,b}, Charlotte Stiplosek^a, Sinead M. O'Donovan^c, David Sinclair^c, Kathleen Grant^d,
Ratna Bollavarapu^b, Donna M. Platt^{a,b}, Craig A. Stockmeier^{a,b}, Barbara Gisabella^{a,b}, Harry
Pantazopoulos^{a,b}

- a) Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS
- b) Program in Neuroscience, University of Mississippi Medical Center, Jackson, MS
- c) Department of Neuroscience, University of Toledo, Toledo, OH
- d) Oregon Primate Research Center, Hillsboro, OR

Address for correspondence:

Harry Pantazopoulos, PhD
Department of Psychiatry and Human Behavior
University of Mississippi School of Medicine
TRC 407
2500 North State St
Jackson, MS 39216, USA
Phone: (601) 815-7983
E-mail: cpantazopoulos@umc.edu

Valeri et al

27 **ABSTRACT**

28 Contextual triggers are significant factors contributing to relapse in substance use disorders (SUD).
29 Emerging evidence points to a critical role of extracellular matrix (ECM) molecules as mediators of reward
30 memories. Chondroitin sulfate proteoglycans (CSPGs) are a subset of ECM molecules that form
31 perineuronal nets (PNN) around inhibitory neurons. PNNs restrict synaptic connections and help maintain
32 synapses. Rodent models suggest that modulation of PNNs may strengthen contextual reward memories
33 in SUD. However, there is currently a lack of information regarding PNNs in the hippocampus of people
34 with SUD as well as how comorbidity with major depressive disorder (MDD) may affect PNNs. We used
35 postmortem hippocampal tissues from cohorts of human and nonhuman primates with or without chronic
36 alcohol use to test the hypothesis that PNNs are increased in subjects with SUD. We used histochemical
37 labeling and quantitative microscopy to examine PNNs, and qRT-PCR to examine gene expression for
38 ECM molecules, synaptic markers and related markers. We identified increased densities of PNNs and
39 CSPG-labeled glial cells in SUD, coinciding with decreased expression of the ECM protease matrix
40 metalloproteinase 9 (*Mmp9*), and increased expression for the excitatory synaptic marker vesicle
41 associated membrane protein 2 (*Vamp2*). Similar increases in PNNs were observed in monkeys with
42 chronic alcohol self-administration. Subjects with MDD displayed changes opposite to SUD, and subjects
43 with SUD and comorbid MDD had minimal changes in any of the outcome measures examined. Our findings
44 demonstrate that PNNs are increased in SUD, possibly contributing to stabilizing contextual reward
45 memories as suggested by preclinical studies. Our results also point to a previously unsuspected role for
46 CSPG expression in glial cells in SUD. Evidence for increased hippocampal PNNs in SUD suggests that
47 targeting PNNs to weaken contextual reward memories is a promising therapeutic approach for SUD,
48 however comorbidity with MDD is a significant consideration.

49

50

51

52

Valeri et al

53 INTRODUCTION

54 Substance use disorders (SUD) are a group of psychiatric disorders with substantially
55 increased risk of mortality and severe socioeconomic burden affecting approximately 7 % of
56 people in the United States annually ^{1, 2}. SUDs impose a substantial burden of morbidity and
57 mortality, exacerbated by persistently high rates of relapse and treatment failure ³. Contextual
58 cues associated with drug use are a critical factor contributing to relapse in individuals with SUD
59 and highlight the strength of memory circuits associated with reward processing ³⁻⁷. A growing
60 number of studies indicate a critical role of extracellular matrix molecules (ECM) in the regulation
61 of reward memories ⁸⁻¹⁷ (for reviews see ^{18, 19}). Recent gene expression profiling studies
62 demonstrate altered expression of pathways involved in ECM regulation in the dorsolateral
63 prefrontal cortex and nucleus accumbens of subjects with opioid use disorder (OUD) ^{12, 20} as well
64 as in preclinical models of OUD ²⁰.

65 Preclinical studies of cocaine, alcohol or opioid use demonstrate that alteration of specialized
66 ECM structures called perineuronal nets (PNN) represent a key feature underlying reward
67 memory in SUDs ^{8, 9, 17, 21-24}. PNNs are ECM structures that envelop populations of fast-firing
68 inhibitory neurons, stabilizing synapses on those neurons and restricting synaptic plasticity ^{16, 22,}
69 ^{25, 26}. During acquisition of drug memories, endogenous proteases including matrix
70 metalloproteases (MMPs) degrade PNN components to allow for formation of new synapses
71 associated with reward memories. ^{11, 27-30}. Chronic drug use resulting in prolonged re-activation of
72 memory circuits results in enhancement of PNN components in the prefrontal cortex and insular
73 cortex, stronger than at baseline, which stabilizes reward-associated synapses ^{9, 23, 24, 31-33} and
74 may contribute to context-induced relapse ^{11, 27-30}. Evidence that intracerebral injection of a
75 pharmacological MMP inhibitor significantly weakens cocaine reward memories provides further
76 support for this hypothesis ¹⁰. The hippocampus is at the center of neurocircuitry involved in
77 reward memory processing ³⁴. Specifically, accumulating evidence suggests that hippocampal

Valeri et al

78 sector CA1 is involved in integrating dopamine reward signaling with contextual memories and in
79 regulating reward expectation and extinction³⁵⁻³⁷. CA1 neurons receive dopaminergic projections
80 from the ventral tegmental area and encode reward-associated spatial memories^{37,38}. CA1 spatial
81 maps are modified by reward expectation and by inhibitory control of excitatory neurons encoding
82 these maps^{37,38}. Inhibitory neurons in CA1 are often surround by PNNs, and alterations of
83 hippocampal PNNs impact several neurotransmitter systems associated with reward processing.
84 For example, PNN degradation alters firing rate of inhibitory parvalbumin (PVB) neurons³⁹, as
85 well as NMDAR/AMPA trafficking⁴⁰ and hippocampal dopamine transmission⁴¹.

86 Despite this evidence, there is a lack of information regarding PNNs in the hippocampus of
87 subjects with SUD, limiting the translatability of preclinical findings and the development of ECM-
88 based therapies for context-induced relapse. Furthermore, subjects with SUD often have
89 comorbid substance use and a high degree of comorbidity with major depressive disorder (MDD)
90⁴². These features are challenging to capture in preclinical models, potentially limiting
91 translatability. We used a cohort of human postmortem samples from subjects with SUD with or
92 without comorbid MDD to test the hypothesis that numerical density of PNNs is increased in sector
93 CA1 of subjects with SUD, accompanied by altered expression of genes related to ECM
94 degradation and biosynthesis, synaptic regulation, and PVB expression. This cohort includes
95 retrospective clinical assessments, toxicology reports, history of substance use and medication
96 history, allowing for testing of several of the features inherent in the population with SUD. Subjects
97 with comorbid SUD and MDD, and subjects with MDD without SUD were included to examine the
98 potential effects of comorbid MDD on ECM pathology in SUD. Furthermore, we used a collection
99 of postmortem hippocampus samples from rhesus monkeys with or without chronic alcohol self-
100 administration to examine the direct cause and effect on PNNs of the most common drug of abuse
101 present across all our subjects with SUD.

102

Valeri et al

103 **MATERIALS AND METHODS**

104 **Postmortem brain samples**

105 *Human subjects for brightfield microscopy and RNA studies*

106 Fresh frozen blocks containing the hippocampus from subjects with SUD (n=20), SUD and
107 comorbid MDD (n=24), MDD (n=20), and psychiatrically normal controls (n=20) were provided by
108 the UMMC Postmortem Brain Core (Table 1, Cohort A). Details are described in our previous
109 report ⁴³ and in the Supplemental Materials.

110 *Psychiatric control subjects for confocal imaging*

111 Paraformaldehyde fixed free-floating samples containing the hippocampus were obtained from a
112 separate cohort of three control subjects from the Harvard Brain Tissue Resource Center (Table
113 1, Cohort B), as fresh frozen tissue is not suitable for reliable immunohistochemical labeling for
114 parvalbumin and synaptic markers. Two psychiatrists determined the absence of DSM-IV
115 diagnoses based on the review of a questionnaire filled out by legal next of kin and a review of all
116 available medical records. Control cases had sufficient information from legally-defined next of
117 kin and medical records to rule out major medical, neurologic, and psychiatric conditions. All
118 brains underwent a complete neuropathological exam and cases with histopathological
119 abnormalities were excluded from this study.

120 *Rhesus macaque subjects*

121 Fresh frozen hippocampus samples from adult male rhesus macaques (*Macaca mulatta*) were
122 obtained from the Monkey Alcohol Tissue Research Resource (MATRR) Cohort 5 (Table 1,
123 Cohort C). Details regarding these subjects are available at www.matrr.com and described in the
124 Supplemental Materials. Subjects were allowed to freely self-administer alcohol for 22 h daily for
125 one year.

Valeri et al

126 **Tissue collection and processing**

127 *Fresh frozen postmortem samples (Cohorts A&C)*

128 Coronal serial sections (14 μm) were obtained from fresh frozen postmortem hippocampal blocks.
129 Blocks were dissected and rapidly frozen in 2-methylbutane and on dry ice without fixation and
130 kept in dry ice before permanent storage at -80 °C. Blocks were sectioned using a Leica CM3050S
131 cryostat.

132 *Paraformaldehyde fixed control subjects (Cohort B)*

133 Tissue blocks containing the hippocampus were processed as described previously ⁴⁴.

134 **Histochemical/immunocytochemical labeling, imaging, and quantification procedures**

135 *Brightfield microscopy*

136 Fresh-frozen, slide-mounted medial hippocampal cryosections from human subjects and rhesus
137 macaque subjects (3-5 sections per subject) were post-fixed for 30 minutes in 4%
138 paraformaldehyde, followed by 1-hour incubation in 2% bovine serum albumin (BSA), and
139 overnight incubation in biotinylated *Wisteria floribunda agglutinin* (WFA) lectin (1:500, catalog #B-
140 1355, Vector Labs). WFA binds to non-sulfated N-acetyl-D-galactosamine residues on the
141 terminal ends of CSPGs ⁴⁵. The following day, tissue was incubated in streptavidin horseradish
142 peroxidase (1:5000 μl , Zymed, San Francisco, CA) for four hours, followed by a 20-minute
143 incubation in 3'3-diaminobenzidine with nickel sulfate hexahydrate and H_2O_2 . Tissue was
144 dehydrated through an ethanol and xylene series, followed by histological labeling with Methyl
145 Green (catalog #H-3402, Vector Labs). Sections were coverslipped and coded for blinded
146 quantitative analysis. All sections included in the study were processed simultaneously to avoid
147 procedural differences. Quantification was performed using an Olympus BX61 microscope and
148 WFA-labeled PNNs were distinguished from WFA+ glial cells based on morphology. Each

Valeri et al

149 anatomical subdivision of the hippocampus was traced for an area measurement using a 20X
150 objective, and WFA-labeled elements were quantified on 40X magnification using Stereo-
151 Investigator v11.

152 *Immunofluorescence and Imaging*

153 Immunofluorescence for VAMP2-PVB-WFA and for GFAP-WFA were conducted as described
154 previously^{46, 47} and in the Supplemental Materials.

155 **Quantitative polymerase chain reaction**

156 qPCR was conducted as described previously^{43, 48} and in the Supplemental Materials. The
157 primers used are listed in Supplemental Table 21.

158 **Statistical Analysis**

159 Numerical densities of microscopy measures were calculated as described in our previous studies
160^{49 46, 47}. The goal of our study was to test for differences in PNN densities in CA1 and hippocampal
161 gene expression of ECM and synaptic markers between diagnosis groups. Analysis of WFA-glia
162 densities was focused on the DG and CA4 areas where these cells are primarily distributed in the
163 hippocampus in our current study and our previous report⁴⁹. Diagnosis groups with comorbid
164 SUD/MDD and MDD were included to test for potential effects of comorbid depression on findings
165 in SUD. Exploratory analysis was conducted on microscopy measures of PNNs and WFA-glia on
166 additional hippocampal sectors. Differences between groups relative to the main outcome
167 measures were assessed for statistical significance using stepwise linear regression analysis of
168 covariance (ANCOVA) using JMP Pro v16.1.0 (SAS Institute Inc., Cary, NC). Logarithmic
169 transformation was applied to values when not normally distributed. Potential confounding
170 variables (Table 1 and Supplementary Tables 5-20) were tested systematically for their effects on
171 main outcome measures and included in the model if they significantly improved goodness-of-fit.
172 Covariates found to significantly affect outcome measures are reported. Subjects with SUD,

Valeri et al

173 subjects with SUD/MDD, and subjects with MDD were first compared separately with
174 psychiatrically-normal controls. Subsequently, the four groups were considered together to test
175 for differences between diagnostic groups and Bonferroni correction applied for multiple
176 comparisons.

177 **RESULTS**

178 **Altered PNN and WFA-glia densities in subjects with SUD, MDD, and comorbid SUD/MDD**

179 Numerical densities of PNNs were significantly increased in CA1 stratum oriens (SO) of subjects
180 with SUD ($p < 0.007$; adjusted for significant effects of PMI and cocaine history). (Figure 1A-E),
181 where the majority of PNNs were distributed in sector CA1 (Control CA1 SO: 3.5 PNNs/mm²;
182 Control CA1 SP: 0.97 PNNs/mm²). Further analysis of additional hippocampal sectors revealed
183 increased numerical densities of PNNs in CA2 SO ($p < 0.03$; adjusted for significant effects of
184 age), CA2 SP ($p < 0.0001$; adjusted for significant effects of cocaine history), CA3 SO ($p < 0.01$;
185 adjusted for significant effects of cocaine history), and CA4 ($p < 0.007$; adjusted for significant
186 effects of cocaine history) in subjects with SUD (Figure 1G, Table S1). History of cocaine use,
187 which was a significant covariate across hippocampal subregions, was associated with decreased
188 PNNs in each of these regions (Figure S4D). No significant differences were found in the dentate
189 gyrus or the CA1 and CA3 SP layers. In subjects with MDD, we observed significantly decreased
190 numerical densities of PNNs in CA1 SO ($p < 0.05$; adjusted for significant effects of sex and
191 calcium channel blockers) and CA1 SP ($p < 0.02$), increased PNNs in CA4 ($p < 0.01$; adjusted for
192 significant effects of anxiety disorder diagnoses), and no significant differences in other regions
193 of the hippocampus. The duration of depression positively correlated with PNN density in CA1
194 SO across subjects with SUD/MDD and MDD (Figure S1A). In subjects with comorbid SUD/MDD,
195 we observed reduced numerical densities of PNNs in CA1 SP ($p < 0.02$; adjusted for significant
196 effects of substance abuse history and duration of MDD, Figure S1B), increased densities of
197 PNNs in CA2 SP ($p < 0.01$; adjusted for significant effects of SSRIs in the toxicology report and

Valeri et al

198 ZT time). No significant differences were observed in the other hippocampal subregions. Table
199 S1 contains information for each hippocampus subregion, including p-values, F-ratios, adjusted
200 least squares means, standard error, and significant covariates.

201 We observed WFA-labeled glial cells in addition to PNN labeling. WFA-glia in our current study
202 were shown to co-express the astrocyte marker glial fibrillary acidic protein (GFAP) (Figure S5)
203 and were morphologically similar to WFA-glia described our previous reports in the human medial
204 temporal lobe^{46, 47}. WFA-glia cells were distributed primarily in the dentate gyrus and CA4 areas,
205 with sparse expression in other hippocampal subregions (Figure 1H-K, N). In subjects with SUD,
206 we observed significantly greater density of WFA-glia in CA4 ($p < 0.002$; adjusted for significant
207 effect of cocaine history), and in the dentate gyrus ($p < 0.02$; adjusted for significant effect of
208 cocaine history, Figure 1L). No other hippocampal subregions displayed statistically significant
209 differences in subjects with SUD. In subjects with MDD, we observed significantly increased
210 densities of WFA-glia in the dentate gyrus ($p < 0.0001$), CA3 SP ($p < 0.0008$; adjusted for a
211 significant effect of antidepressants in last month of life), CA2 SP ($p < 0.006$; adjusted for a
212 significant effect of antidepressants in last month of life), and CA2 SO ($p < 0.02$). All other
213 hippocampal subregions lacked differences in subjects with MDD. In subjects with comorbid
214 SUD/MDD, we observed significantly decreased numerical densities of WFA-glia in the dentate
215 gyrus ($p < 0.02$; adjusted for significant effects of alcohol in the toxicology report and calcium
216 channel blockers), CA4 ($p < 0.02$; adjusted for a significant effect of alcohol in the toxicology
217 report), CA3 SP ($p < 0.002$; adjusted for significant effects of alcohol in the toxicology report and
218 race), CA2 SP ($p < 0.004$; adjusted for a significant effect of race), CA1 SP ($p < 0.02$; adjusted
219 for significant effects of antipsychotics and alcohol in the toxicology report), and CA1 SO ($p <$
220 0.02 ; adjusted for a significant effect of race) when compared to psychiatric control subjects. Table
221 S2 contains information for each hippocampus subregion. No differences in hippocampal area

Valeri et al

222 measurements were detected between control subjects and any of the diagnosis groups
223 (Supplementary Table S4).

224 **Gene expression of markers for cell populations associated with PNNs and WFA-glial cells**

225 *Parvalbumin*. Neurons expressing parvalbumin (*Pvb*) mRNA represent the majority of neurons
226 surrounded by PNNs in the hippocampus⁴⁹⁻⁵¹. Subjects with SUD had significantly greater gene
227 expression of *Pvb* compared to control subjects (Fig. 1F, Table S3; $p < 0.007$; adjusted for a
228 significant effect of cocaine history). Subjects in the SUD group with cocaine in the blood at death
229 had significantly lower *Pvb* gene expression compared to subjects with SUD without cocaine in
230 the blood at death (Supplemental Figure S4B). *Pvb* mRNA was also significantly greater in
231 subjects with comorbid SUD/MDD ($p < 0.008$), and subjects with MDD ($p < 0.005$) compared to
232 control subjects (Fig. 1F, Table S3).

233 *Glial fibrillary acidic protein*. The astrocyte marker glial fibrillary acidic protein (*Gfap*) colocalized
234 with astrocytes labeled by WFA (Figure S5), which is in line with previous reports from human
235 postmortem studies^{46, 52}. *Gfap* gene expression was significantly lower in the hippocampus of
236 subjects with comorbid SUD/MDD ($p < 0.02$; adjusted for significant effects of SSRIs in last month
237 of life which increases *Gfap*) (Fig. 1M, Table S3). No changes were detected in the SUD or MDD
238 groups.

239 **Altered expression of synaptic markers in the hippocampus of subjects with SUD**

240 *Synaptobrevin and Synapsin 1*. Synaptobrevin (VAMP2) is an excitatory synaptic marker that
241 contributes to the SNARE complex, allowing for fusion of vesicles to the cell membrane to facilitate
242 neurotransmitter exocytosis and receptor trafficking^{53, 54}. We examined VAMP2 as a step towards
243 altered synaptic regulation in the hippocampus of subjects with SUD as suggested by extensive
244 literature indicating altered synaptic regulation by chronic exposure to substances of abuse (for
245 review see⁵⁵). We first tested whether VAMP2 protein is located on PVB neurons and in PNNs,

Valeri et al

246 and observed VAMP2 protein on PVB neurons ensheathed by PNNs and enmeshed within the
247 PNN (Figure 2B-E). In subjects with SUD, *Vamp2* mRNA was significantly increased ($p < 0.04$;
248 adjusted for a significant effect of sleep quality). An increase in *Vamp2* transcription was also
249 observed in subjects with MDD ($p < 0.005$; with significant effects of age, ZT time, and sleep
250 disturbance). No changes in *Vamp2* expression were detected in subjects with comorbid
251 SUD/MDD. We conducted similar analysis for the inhibitory presynaptic marker, synapsin 1
252 (*Syn1*). We observed spatial overlap of SYN1 protein with PVB interneurons coated by PNNs,
253 including SYN1 within PNNs (Figure 2G-J). In contrast to *Vamp2*, no significant differences were
254 observed for *Syn1* gene expression in any of the diagnostic groups (Figure 2F).

255 **Altered expression of ECM molecules in the hippocampus of subjects with SUD**

256 *Matrix metalloproteinase 9 (Mmp9) and Cathepsin S (Ctss)*. Significantly decreased expression
257 of *Mmp9* was observed in subjects with SUD (Figure 3A: $p < 0.04$). Furthermore, *Ctss* mRNA was
258 significantly decreased in subjects with SUD (Figure 3B, S4: $p < 0.03$; with significant effects of
259 cocaine in the toxicology report), and increased in subjects with MDD ($p < 0.04$; adjusted for
260 significant effects of alcohol use severity and ZT time). No significant changes were observed in
261 subjects with comorbid SUD/MDD (Figure 3A-B).

262 *Aggrecan and Chondroitin synthase 1*. In subjects with SUD/MDD, we observed significantly
263 increased aggrecan (*Acan*) (Figure 3C: $p < 0.03$), as well as chondroitin synthase 1 (*Chsy1*)
264 mRNA (Figure 3D, S3B: $p < 0.0001$; with significant effects of duration of AUD and tissue pH). In
265 subjects with SUD, a significant increase in *Chsy1* expression was detected (Figure 3C, S3: $p <$
266 0.04 ; with a significant effect of tissue pH), and no significant difference was observed for *Acan*
267 (Figure 3D). No changes were observed in subjects with MDD for either *Acan* or *Chsy1* (Figure
268 3C&D).

Valeri et al

269 **Increased numerical densities of perineuronal nets in the hippocampus of monkeys with**
270 **chronic alcohol self-administration**

271 We observed a significant increase of PNNs in the combined hippocampal subfields in rhesus
272 monkeys with chronic alcohol self-administration ($p < 0.03$). Similar increases were observed in
273 CA1 SO (Figure 4E; $p < 0.04$), CA3 SO (Figure 4E; $p < 0.03$), and CA3 SP (Figure 4E; $p < 0.03$).
274 We also detected significantly increased numerical densities of WFA-labeled glia in the dentate
275 gyrus granule cell layer (Fig. 4F; $p < 0.04$).

276 **DISCUSSION**

277 Our data represent, to our knowledge, the first evidence for increased PNN densities in
278 subjects with SUD and rhesus macaques with chronic alcohol self-administration. These findings
279 link over a decade of evidence from preclinical models demonstrating increased PNNs in animals
280 with chronic drug use^{9, 17, 23, 24, 32, 56-58} with evidence in subjects with SUD. Together with the
281 observed increased expression of the synaptic marker *Vamp2* and the CSPG synthesis molecule
282 *Chsy1*, this suggests that enhanced PNN composition may aid in stabilizing contextual reward-
283 associated synapses in the CA1 hippocampus of individuals with SUD. CA1 hippocampal neurons
284 receive dopaminergic projections from the ventral tegmental area and encode reward-related
285 spatial memories^{37, 38}. These CA1 spatial maps are modulated by local inhibitory control of
286 excitatory neurons that encode the spatial map^{37, 38}. Speculatively, increased PNNs in CA1 of
287 subjects with SUD may contribute to selective inhibitory control of excitatory neurons to sustain
288 spatial maps involved in drug reward memories. Contextual memory processing may differ
289 between drugs of abuse, and preclinical studies report decreases or no change in PNN densities
290 with some drug classes including chronic nicotine, cocaine or opioid exposure^{17, 21, 31}. Our findings
291 represent hippocampal alterations in subjects with polysubstance use which consists of a
292 significant population of people seeking treatment for SUDs. Similar findings in nonhuman
293 primates with chronic alcohol use together with increased PNNs in preclinical models of cocaine

Valeri et al

294 suggests that increased PNN densities may be a shared feature in people with polysubstance
295 use disorder which often includes alcohol use disorder^{9, 24, 32, 59, 60}. Furthermore, decreased
296 expression of ECM proteolytic molecules indicates that changes in PNN densities are
297 accompanied by decreased ECM remodeling in chronic SUD. Increased expression of
298 parvalbumin, expressed by neurons that PNNs typically encapsulate, suggests increased
299 feedforward inhibition of local excitatory pyramidal neurons by parvalbumin that may enhance
300 coherence of drug-associated neuronal ensembles. In contrast, decreased densities of PNNs in
301 subjects with MDD represent the first evidence for altered PNNs in the hippocampus of subjects
302 with MDD. Taken together, our findings support the hypothesis that increased PNNs may stabilize
303 contextual reward memories in subjects with SUD and thus may represent therapeutic targets for
304 context-induced relapse. Furthermore, decreased densities of PNNs in subjects with MDD and
305 lack of significant differences in subjects with comorbid SUD/MDD highlight the importance of
306 considering comorbid conditions for the neuropathology of SUD.

307

308 *PNNs and ECM molecules in the Hippocampus of Subjects with Substance Use Disorder*

309 Our findings support an increasing number of preclinical studies demonstrating that PNNs
310 stabilize reward memories^{8, 9, 16, 17, 22-24, 33}. Furthermore, PNNs are involved in a wide range of
311 processes that can impact context-induced relapse including stabilization of synapses, receptor
312 trafficking, and regulation of interneuron activity^{25, 26, 39, 40, 61-67}. Previous studies have implicated
313 each of these processes in SUD. For example, chronic substance use has been shown to elicit
314 downstream alteration of synapses and neurotransmitters including changes in dopamine 2
315 receptors (D2R)⁶⁸ as well as glutamatergic and GABAergic systems^{69, 70}. SUDs are chronically
316 relapsing disorders which rely heavily on memory salience (i.e., cue responsiveness). PNNs
317 contribute to synaptic homeostasis through the stabilization of synapses and PVB interneuron-

Valeri et al

318 mediated excitatory/inhibitory balance ⁷¹. Thus, PNNs may stabilize synapses involved in drug
319 reward processes that contribute to context-induced relapse ¹⁸.

320 The association of PVB interneurons with PNNs has been demonstrated in several brain
321 areas, including the hippocampus ^{49, 72-74}. Hippocampal PVB neurons are predominantly located
322 in the SO layers of the CA regions. PVB neurons are involved in modulating glutamatergic
323 neurons and hippocampal output to brain regions involved in reward processing ^{75, 76}. Increased
324 PVB expression is positively correlated with PNN labeling ⁷⁷ and removal of PNNs with
325 chondroitinase ABC or antidepressants decreases PVB interneuron activity ⁷⁸. Increased
326 parvalbumin (PVB) expression in SUD may induce feedforward inhibition of local excitatory
327 neurons that enhances coherence of drug-specific neuronal ensembles ⁷⁹. Enhanced PNN
328 composition on PVB neurons may also contribute to increased PVB expression and downstream
329 consequences on excitatory/inhibitory balance which can result in altered activity of reward
330 circuits involved in reward prediction and impulsivity ^{80, 81}. Importantly, *Pvb* expression was
331 significantly decreased in subjects with cocaine in their toxicology reports (Supplementary Figure
332 1G), suggesting that cocaine temporarily blunts PVB expression to disinhibit excitatory neurons
333 ⁵⁷. Furthermore, decreased ECM proteolytic gene expression (*Mmp9* and *Ctss*) in subjects with
334 SUD is in line with increased PNN densities in these subjects and with preclinical models of
335 hippocampal MMP9 expression in alcohol use ⁸², potentially suggesting hypofunction of PNN
336 proteolytic systems in SUD ⁸³. In our ANCOVA models, subjects with SUD who had cocaine in
337 their toxicology reports had greater expression of *Ctss* (Supplementary Figure 1H). Speculatively,
338 increased *Ctss* and decreased *Pvb* in subjects with cocaine in the toxicology report may indicate
339 that cocaine temporally activates *Ctss* to temporarily degrade PNNs and decrease in *Pvb*
340 expression.

341 There is extensive evidence demonstrating a central role of the hippocampus for episodic
342 memory processing ⁸⁴. Furthermore, the hippocampus has bi-directional connections with the

Valeri et al

343 amygdala that contribute to assigning emotional valence to contextual memories, which is crucial
344 in the long-term retention of drug memories⁸⁵. Hippocampal connections with the ventral
345 tegmental area (VTA) are involved in regulating memory salience and reward predictions.
346 Hippocampal glutamatergic fibers from CA1 travel through the subiculum to basal forebrain
347 structures, and synapse onto VTA neurons which feed back to the hippocampus to release
348 dopamine^{80, 81}. Thus, increased PNNs in the hippocampus of subjects with SUD can impact this
349 system and contribute to several aspects of reward memory circuits.

350 Our studies represent first description of increased numerical densities of WFA-glia cells in
351 individuals with SUD. Despite previous evidence that WFA-glia colocalize with the astrocytic
352 marker GFAP^{46, 47}, we did not detect increased GFAP expression in subjects with SUD,
353 suggesting that increases in WFA-glia do not reflect a broader astrogliosis process. Increased
354 WFA-glia in the hippocampus may indicate increased CSPG production by glia contributing to
355 increased PNNs in SUD.

356 We used a proximal specie, *Macaca mulatta*, with or without chronic alcohol use to test for
357 specific effects of the most common drug in our cohort without the covariates inherent to cross-
358 sectional human studies. Increased PNN densities and WFA-glia in rhesus monkeys with chronic
359 alcohol use provides support for our findings in human subjects. Furthermore, the ability of chronic
360 alcohol use alone to create these changes is intriguing and represents the first evidence for
361 increased PNNs in the hippocampus of non-human primates in response to any drug of abuse.
362 The present findings also represent the first observation of WFA-labeled glia in the non-human
363 primate brain; to this point, they have only been reported in human subjects^{46, 49, 73}. These WFA-
364 glial cell increases may represent enhanced CSPG synthesis by astrocytes.

365 *PNNs and ECM molecules in the Hippocampus of Subjects with Comorbid Substance Use*
366 *Disorder and Major Depressive Disorder*

Valeri et al

367 Subjects with comorbid SUD and MDD represent a significant population of people with SUD
368 and a bi-directional disorder where dysphoria can fuel the inclination to self-medicate.
369 Alternatively, chronic drug use can contribute to mood disturbances⁸⁶. Approximately one third
370 of patients with MDD also experience SUD, and conversely a substantial proportion of individuals
371 with SUD will experience MDD at some point during prognosis^{42,87}. This bi-directional comorbidity
372 contributes to a heightened risk of suicide and greater social and personal impairment⁸⁸. Despite
373 this relationship, co-occurrence of MDD and SUD is not typically examined in postmortem brain
374 studies. Our results suggest MDD comorbidity is an important factor in studies of SUD. Inclusion
375 of subjects with MDD may either mask or amplify changes present in each disorder. Most of our
376 outcome measures displayed opposing directionality between subjects with SUD and MDD. For
377 example, density of CA1 SO PNNs was significantly increased in SUD, decreased in MDD, and
378 unaltered in subjects with comorbid SUD/MDD. In comparison, a comorbid diagnosis of MDD
379 appeared to significantly amplify the existing increased expression of *Chsy1* observed in subjects
380 with SUD (Figure 3D).

381 Increased expression of *Chsy1* in SUD and subjects with SUD/MDD may suggest that
382 increased biosynthesis of CSPGs by chronic drug use is enhanced by processes underlying MDD.
383 Expression of the CSPG aggrecan, a major PNN component⁸⁹, was increased in subjects with
384 comorbid SUD/MDD. This may represent alterations in PNN composition that are not detected by
385 standard WFA labeling.

386 *PNNs and ECM molecules in the Hippocampus of Subjects with Major Depressive Disorder*

387 A strength of our cohort was the ability to cross-examine the incidence of MDD comorbid with
388 SUD as well as subjects with MDD only. While densities of PNNs were decreased in subjects with
389 MDD (Fig. 1C), the duration of MDD positively correlated with densities of PNNs in CA1 SO
390 (Supplementary Figure 1A). This is in line with preclinical evidence demonstrating that animals
391 exposed to chronic social defeat display increased PNNs in the hippocampus⁹⁰. Over time,

Valeri et al

392 increased PNNs may alter E/I balance contributing to decreased hippocampal sharp wave ripple
393 events that negatively affect mood and memory ^{91, 92}. Increased expression of VAMP2 in subjects
394 with MDD is in line with preclinical evidence for glucocorticoid-mediated calcium influx increases
395 in hippocampal CA regions which perturbs plasticity, potentially resulting in poorer cognitive
396 performance ⁹³. Increased VAMP2 is also in agreement with evidence indicating altered synaptic
397 markers in MDD ⁹⁴. Decreases in PNNs may result in reduced stabilization of synapses and
398 contribute to synaptic alterations, potentially resulting in memory impairment, memory
399 generalization, and cognitive deficits observed in MDD ⁹⁵. An extensive number of studies
400 implicate glial cell alterations in the pathology of depression (for review see ⁹⁶). In patients with
401 SUD/MDD, we observed decreased expression of *Gfap*. A similar nonsignificant trend for
402 decreased *Gfap* expression was observed in subjects with MDD. In our ANCOVA models, *Gfap*
403 expression was significantly affected by history of SSRI exposure, which was positively
404 associated with *Gfap* expression (Supplementary Figure 1B), suggesting that therapeutic effects
405 of SSRIs may in part normalize *Gfap* levels. Our observed increase of *Ctss* gene expression may
406 represent a heightened inflammatory state in the hippocampus of subjects with MDD, which has
407 been extensively implicated in MDD ^{97, 98}, including in the hippocampus in a cohort that largely
408 overlaps with our cohort of subjects with MDD ⁹⁹.

409 **TECHNICAL CONSIDERATIONS**

410 Several factors represent challenges in examining molecular pathology in the brain of subjects
411 with SUD, including polysubstance use, comorbidity with MDD, and pharmacological treatments.
412 However, considering that this is representative of the real-world population of SUD it is important
413 to examine the molecular pathology when these factors are present in the same subjects when
414 considering development of therapeutic treatment strategies for this population. Our cohort
415 consists of extensive information including retrospective clinical assessments, history of specific
416 drugs of abuse and presence or absence of drugs of abuse and psychiatric medications in the

Valeri et al

417 blood at death from toxicology reports that can be accounted for using ANCOVA analyses, as
418 conducted in our previous study using this same cohort ⁴³. Furthermore, the inclusion of samples
419 from rhesus monkeys with chronic alcohol use provides a valuable cause and effect comparison
420 for the most common drug of abuse in our human subjects. The development of additional
421 collections of NHP brain samples containing subjects self-administering specific drugs of abuse
422 alone or in combination would further aide in interpreting human postmortem brain studies and
423 guiding strategies for novel treatment development. For our microscopy studies, use of WFA lectin
424 provides a standard view of a specific population of PNNs, as it binds to non-sulfated N-acetyl-D-
425 galactosamine ⁴⁵. There are other populations of PNNs that can be detected with alternative
426 labeling methods which may surround complementary populations of neurons ¹⁰⁰. Future studies
427 with additional markers for PNN core proteins and sulfation motifs will provide insight into the
428 specific components of PNNs in SUD. Further, our fresh frozen postmortem tissue has inherent
429 technical limitations including lack of ability to conduct PVB-immunolabeling as well as reliable
430 immunolabeling of synaptic markers, therefore mRNA measures were used for these markers.
431 Measurements of mRNA by qPCR do not identify the cell-types responsible for synthesis or
432 functional activity of any of the genes measured.

433 **CONCLUSIONS**

434 In summary, our findings represent the first evidence for increased numerical densities of
435 PNNs in the hippocampus of human subjects with SUD. Increased densities of hippocampal
436 PNNs, together with decreased expression of ECM proteolytic genes and altered synaptic
437 markers supports preclinical studies that suggest that PNNs may stabilize reward memories.
438 Thus, PNNs and ECM molecules may represent promising targets for addressing cue-induced
439 relapse in SUD. In comparison, subjects with MDD displayed generally opposite effects for many
440 of the main outcome measures and subjects with SUD with a comorbid diagnosis of MDD

Valeri et al

441 suggesting that ECM changes in MDD oppose changes in SUD. These findings highlight the
442 importance of considering comorbidities regarding SUD pathology and treatment strategies.

443

444 **Funding:** This work was funded by support from the National Institute of Mental Health (R01
445 MH125833 and R01 MH117460), the National Institute of Alcoholism and Alcohol Abuse (F31
446 AA030166 and R01 AA029023), and the Postmortem Brain Core of the Center for Psychiatric
447 Neuroscience, funded through an IDeA COBRE award from the National Institute of General
448 Medical Sciences (P30 GM103328).

449 **Acknowledgements:** The authors deeply appreciate the invaluable contributions made by the
450 families consenting to donate brain tissue and be interviewed. We also gratefully acknowledge
451 the support of the staff of the Cuyahoga County Medical Examiner's Office, Cleveland, Ohio. We
452 acknowledge the expert assistance of Drs. James C. Overholser, George Jurjus, Lisa C. Konick,
453 and of Lesa Dieter in establishing the psychiatric diagnoses, acquiring written consent and in
454 collecting the tissues. For some of the subjects, the services of Timothy M. De Jong in acquiring
455 written consent and Lisa Larkin and Nicole Herbst in tissue collection are gratefully acknowledged.

456 **Conflict of Interest Statement:** The authors have no competing financial interests to disclose.

457

458 **Data Availability Statement:** The data and original contributions presented in this study are
459 included in the manuscript or supplemental materials. Further inquiries can be directed to the
460 corresponding author.

461

462

463 **REFERENCES**

Valeri et al

- 464 1. Grant BF, Saha TD, Ruan WJ, Goldstein RB, Chou SP, Jung J *et al*. Epidemiology of DSM-5 Drug Use
465 Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III.
466 *JAMA Psychiatry* 2016; **73**(1): 39-47.
- 467
- 468 2. SAMHSA. Key substance use and mental health indicators in the United States: Results from the
469 2017 National Survey on Drug Use and Health. In: Services USDoHaH (ed). www.samhsa.gov/data,
470 2018.
- 471
- 472 3. Zironi I, Burattini C, Aicardi G, Janak PH. Context is a trigger for relapse to alcohol. *Behav Brain Res*
473 2006; **167**(1): 150-155.
- 474
- 475 4. Carter BL, Tiffany ST. Meta-analysis of cue-reactivity in addiction research. *Addiction* 1999; **94**(3):
476 327-340.
- 477
- 478 5. Niaura RS, Rohsenow DJ, Binkoff JA, Monti PM, Pedraza M, Abrams DB. Relevance of cue reactivity
479 to understanding alcohol and smoking relapse. *J Abnorm Psychol* 1988; **97**(2): 133-152.
- 480
- 481 6. Weiss F. Neurobiology of craving, conditioned reward and relapse. *Curr Opin Pharmacol* 2005;
482 **5**(1): 9-19.
- 483
- 484 7. Janak PH, Chaudhri N. The Potent Effect of Environmental Context on Relapse to Alcohol-Seeking
485 After Extinction. *Open Addict J* 2010; **3**: 76-87.
- 486
- 487 8. Xue YX, Xue LF, Liu JF, He J, Deng JH, Sun SC *et al*. Depletion of perineuronal nets in the amygdala
488 to enhance the erasure of drug memories. *J Neurosci* 2014; **34**(19): 6647-6658.
- 489
- 490 9. Slaker M, Churchill L, Todd RP, Blacktop JM, Zuloaga DG, Raber J *et al*. Removal of perineuronal
491 nets in the medial prefrontal cortex impairs the acquisition and reconsolidation of a cocaine-
492 induced conditioned place preference memory. *J Neurosci* 2015; **35**(10): 4190-4202.
- 493
- 494 10. Brown TE, Forquer MR, Cocking DL, Jansen HT, Harding JW, Sorg BA. Role of matrix
495 metalloproteinases in the acquisition and reconsolidation of cocaine-induced conditioned place
496 preference. *Learn Mem* 2007; **14**(3): 214-223.
- 497
- 498 11. Smith AW, Nealey KA, Wright JW, Walker BM. Plasticity associated with escalated operant ethanol
499 self-administration during acute withdrawal in ethanol-dependent rats requires intact matrix
500 metalloproteinase systems. *Neurobiol Learn Mem* 2011; **96**(2): 199-206.
- 501
- 502 12. Seney ML, Kim SM, Glausier JR, Hildebrand MA, Xue X, Zong W *et al*. Transcriptional Alterations
503 in Dorsolateral Prefrontal Cortex and Nucleus Accumbens Implicate Neuroinflammation and
504 Synaptic Remodeling in Opioid Use Disorder. *Biol Psychiatry* 2021; **90**(8): 550-562.

Valeri et al

- 505
506 13. Browne CJ, Futamura R, Minier-Toribio A, Hicks EM, Ramakrishnan A, Martínez-Rivera F *et al.*
507 Transcriptional signatures of heroin intake and seeking throughout the brain reward circuit.
508 *bioRxiv* 2023: 2023.2001.2011.523688.
- 509
510 14. Chioma VC, Kruyer A, Bobadilla AC, Angelis A, Ellison Z, Hodebourg R *et al.* Heroin Seeking and
511 Extinction From Seeking Activate Matrix Metalloproteinases at Synapses on Distinct
512 Subpopulations of Accumbens Cells. *Biol Psychiatry* 2021; **89**(10): 947-958.
- 513
514 15. Smith AC, Scofield MD, Kalivas PW. The tetrapartite synapse: Extracellular matrix remodeling
515 contributes to corticoaccumbens plasticity underlying drug addiction. *Brain Res* 2015; **1628**(Pt A):
516 29-39.
- 517
518 16. Slaker M, Blacktop JM, Sorg BA. Caught in the Net: Perineuronal Nets and Addiction. *Neural Plast*
519 2016; **2016**: 7538208.
- 520
521 17. Roura-Martinez D, Diaz-Bejarano P, Ucha M, Paiva RR, Ambrosio E, Higuera-Matas A. Comparative
522 analysis of the modulation of perineuronal nets in the prefrontal cortex of rats during protracted
523 withdrawal from cocaine, heroin and sucrose self-administration. *Neuropharmacology* 2020; **180**:
524 108290.
- 525
526 18. Valeri J, Gisabella B, Pantazopoulos H. Dynamic regulation of the extracellular matrix in reward
527 memory processes: a question of time. *Frontiers in cellular neuroscience* 2023; **17**: 1208974.
- 528
529 19. Ray MH, Williams BR, Kuppe MK, Bryant CD, Logan RW. A Glitch in the Matrix: The Role of
530 Extracellular Matrix Remodeling in Opioid Use Disorder. *Front Integr Neurosci* 2022; **16**: 899637.
- 531
532 20. Browne CJ, Futamura R, Minier-Toribio A, Hicks EM, Ramakrishnan A, Martinez-Rivera FJ *et al.*
533 Transcriptional signatures of heroin intake and relapse throughout the brain reward circuitry in
534 male mice. *Sci Adv* 2023; **9**(23): eadg8558.
- 535
536 21. Vazquez-Sanroman DB, Monje RD, Bardo MT. Nicotine self-administration remodels perineuronal
537 nets in ventral tegmental area and orbitofrontal cortex in adult male rats. *Addict Biol* 2017; **22**(6):
538 1743-1755.
- 539
540 22. Fawcett JW, Fyhn M, Jendelova P, Kwok JCF, Ruzicka J, Sorg BA. The extracellular matrix and
541 perineuronal nets in memory. *Mol Psychiatry* 2022; **27**(8): 3192-3203.
- 542
543 23. Lasek AW, Chen H, Chen WY. Releasing Addiction Memories Trapped in Perineuronal Nets. *Trends*
544 *Genet* 2018; **34**(3): 197-208.
- 545

Valeri et al

- 546 24. Chen H, He D, Lasek AW. Repeated Binge Drinking Increases Perineuronal Nets in the Insular
547 Cortex. *Alcohol Clin Exp Res* 2015; **39**(10): 1930-1938.
- 548
- 549 25. Gogolla N, Caroni P, Luthi A, Herry C. Perineuronal nets protect fear memories from erasure.
550 *Science* 2009; **325**(5945): 1258-1261.
- 551
- 552 26. Pizzorusso T, Medini P, Berardi N, Chierzi S, Fawcett JW, Maffei L. Reactivation of ocular
553 dominance plasticity in the adult visual cortex. *Science* 2002; **298**(5596): 1248-1251.
- 554
- 555 27. Wright JW, Masino AJ, Reichert JR, Turner GD, Meighan SE, Meighan PC *et al*. Ethanol-induced
556 impairment of spatial memory and brain matrix metalloproteinases. *Brain Res* 2003; **963**(1-2):
557 252-261.
- 558
- 559 28. Natarajan R, Harding JW, Wright JW. A role for matrix metalloproteinases in nicotine-induced
560 conditioned place preference and relapse in adolescent female rats. *J Exp Neurosci* 2013; **7**: 1-14.
- 561
- 562 29. Smith AC, Kupchik YM, Scofield MD, Gipson CD, Wiggins A, Thomas CA *et al*. Synaptic plasticity
563 mediating cocaine relapse requires matrix metalloproteinases. *Nat Neurosci* 2014; **17**(12): 1655-
564 1657.
- 565
- 566 30. Stefaniuk M, Beroun A, Lebitko T, Markina O, Leski S, Meyza K *et al*. Matrix Metalloproteinase-9
567 and Synaptic Plasticity in the Central Amygdala in Control of Alcohol-Seeking Behavior. *Biol*
568 *Psychiatry* 2017; **81**(11): 907-917.
- 569
- 570 31. Van den Oever MC, Lubbers BR, Goriounova NA, Li KW, Van der Schors RC, Loos M *et al*.
571 Extracellular matrix plasticity and GABAergic inhibition of prefrontal cortex pyramidal cells
572 facilitates relapse to heroin seeking. *Neuropsychopharmacology* 2010; **35**(10): 2120-2133.
- 573
- 574 32. Slaker ML, Jorgensen ET, Hegarty DM, Liu X, Kong Y, Zhang F *et al*. Cocaine Exposure Modulates
575 Perineuronal Nets and Synaptic Excitability of Fast-Spiking Interneurons in the Medial Prefrontal
576 Cortex. *eNeuro* 2018; **5**(5).
- 577
- 578 33. Lasek AW. Effects of Ethanol on Brain Extracellular Matrix: Implications for Alcohol Use Disorder.
579 *Alcohol Clin Exp Res* 2016; **40**(10): 2030-2042.
- 580
- 581 34. Goode TD, Maren S. Common neurocircuitry mediating drug and fear relapse in preclinical
582 models. *Psychopharmacology (Berl)* 2019; **236**(1): 415-437.
- 583
- 584 35. Goldsmith SK, Joyce JN. Dopamine D2 receptor expression in hippocampus and parahippocampal
585 cortex of rat, cat, and human in relation to tyrosine hydroxylase-immunoreactive fibers.
586 *Hippocampus* 1994; **4**(3): 354-373.

Valeri et al

- 587
588 36. Galvez-Marquez DK, Salgado-Menez M, Moreno-Castilla P, Rodriguez-Duran L, Escobar ML,
589 Tecuapetla F *et al.* Spatial contextual recognition memory updating is modulated by dopamine
590 release in the dorsal hippocampus from the locus coeruleus. *Proc Natl Acad Sci U S A* 2022;
591 **119**(49): e2208254119.
- 592
593 37. Krishnan S, Heer C, Cherian C, Sheffield MEJ. Reward expectation extinction restructures and
594 degrades CA1 spatial maps through loss of a dopaminergic reward proximity signal. *Nature*
595 *communications* 2022; **13**(1): 6662.
- 596
597 38. Trouche S, Perestenko PV, van de Ven GM, Bratley CT, McNamara CG, Campo-Urriza N *et al.*
598 Recoding a cocaine-place memory engram to a neutral engram in the hippocampus. *Nat Neurosci*
599 2016; **19**(4): 564-567.
- 600
601 39. Wingert JC, Sorg BA. Impact of Perineuronal Nets on Electrophysiology of Parvalbumin
602 Interneurons, Principal Neurons, and Brain Oscillations: A Review. *Front Synaptic Neurosci* 2021;
603 **13**: 673210.
- 604
605 40. Frischknecht R, Heine M, Perrais D, Seidenbecher CI, Choquet D, Gundelfinger ED. Brain
606 extracellular matrix affects AMPA receptor lateral mobility and short-term synaptic plasticity. *Nat*
607 *Neurosci* 2009; **12**(7): 897-904.
- 608
609 41. Shah A, Lodge DJ. A loss of hippocampal perineuronal nets produces deficits in dopamine system
610 function: relevance to the positive symptoms of schizophrenia. *Transl Psychiatry* 2013; **3**(1): e215.
- 611
612 42. Mueller TI, Lavori PW, Keller MB, Swartz A, Warshaw M, Hasin D *et al.* Prognostic effect of the
613 variable course of alcoholism on the 10-year course of depression. *Am J Psychiatry* 1994; **151**(5):
614 701-706.
- 615
616 43. Valeri J, O'Donovan SM, Wang W, Sinclair D, Bollavarapu R, Gisabella B *et al.* Altered expression
617 of somatostatin signaling molecules and clock genes in the hippocampus of subjects with
618 substance use disorder. *Front Neurosci* 2022; **16**: 903941.
- 619
620 44. Konradi C, Yang CK, Zimmerman EI, Lohmann KM, Gresch P, Pantazopoulos H *et al.* Hippocampal
621 interneurons are abnormal in schizophrenia. *Schizophr Res* 2011; **131**(1-3): 165-173.
- 622
623 45. Nadanaka S, Miyata S, Yaqiang B, Tamura JI, Habuchi O, Kitagawa H. Reconsideration of the
624 Semaphorin-3A Binding Motif Found in Chondroitin Sulfate Using Galnac4s-6st-Knockout Mice.
625 *Biomolecules* 2020; **10**(11).
- 626

Valeri et al

- 627 46. Pantazopoulos H, Murray EA, Berretta S. Total number, distribution, and phenotype of cells
628 expressing chondroitin sulfate proteoglycans in the normal human amygdala. *Brain Res* 2008;
629 **1207**: 84-95.
- 630
- 631 47. Pantazopoulos H, Woo TU, Lim MP, Lange N, Berretta S. Extracellular matrix-glial abnormalities in
632 the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. *Arch Gen Psychiatry*
633 2010; **67**(2): 155-166.
- 634
- 635 48. O'Donovan SM, Sullivan C, Koene R, Devine E, Hasselfeld K, Moody CL *et al*. Cell-subtype-specific
636 changes in adenosine pathways in schizophrenia. *Neuropsychopharmacology* 2018; **43**(8): 1667-
637 1674.
- 638
- 639 49. Pantazopoulos H, Sawyer C, Heckers S, Berretta S, Markota M. Chondroitin Sulfate Proteoglycan
640 Abnormalities in the Hippocampus of Subjects with Schizophrenia. *Neuropsychopharmacology*
641 2014; **39**: S298-S299.
- 642
- 643 50. Yamada J, Jinno S. Spatio-temporal differences in perineuronal net expression in the mouse
644 hippocampus, with reference to parvalbumin. *Neuroscience* 2013; **253**: 368-379.
- 645
- 646 51. Rogers SL, Rankin-Gee E, Risbud RM, Porter BE, Marsh ED. Normal Development of the
647 Perineuronal Net in Humans; In Patients with and without Epilepsy. *Neuroscience* 2018; **384**: 350-
648 360.
- 649
- 650 52. Pantazopoulos H, Woo TU, Lim MP, Lange N, Berretta S. Extracellular matrix-glial abnormalities in
651 the amygdala and entorhinal cortex of subjects diagnosed with schizophrenia. *Archives of general*
652 *psychiatry* 2010; **67**(2): 155-166.
- 653
- 654 53. Yan C, Jiang J, Yang Y, Geng X, Dong W. The function of VAMP2 in mediating membrane fusion:
655 An overview. *Frontiers in Molecular Neuroscience* 2022; **15**.
- 656
- 657 54. Torres VI, Vallejo D, Inestrosa NC. Emerging Synaptic Molecules as Candidates in the Etiology of
658 Neurological Disorders. *Neural Plast* 2017; **2017**: 8081758.
- 659
- 660 55. Neuhofer D, Kalivas P. Metaplasticity at the addicted tetrapartite synapse: A common
661 denominator of drug induced adaptations and potential treatment target for addiction.
662 *Neurobiology of Learning and Memory* 2018; **154**: 97-111.
- 663
- 664 56. Gonzalez AE, Jorgensen ET, Ramos JD, Harkness JH, Aadland JA, Brown TE *et al*. Impact of
665 Perineuronal Net Removal in the Rat Medial Prefrontal Cortex on Parvalbumin Interneurons After
666 Reinstatement of Cocaine Conditioned Place Preference. *Front Cell Neurosci* 2022; **16**: 932391.
- 667

Valeri et al

- 668 57. Jorgensen ET, Gonzalez AE, Harkness JH, Hegarty DM, Thakar A, Burchi DJ *et al.* Cocaine memory
669 reactivation induces functional adaptations within parvalbumin interneurons in the rat medial
670 prefrontal cortex. *Addict Biol* 2021; **26**(3): e12947.
- 671
- 672 58. Blacktop JM, Sorg BA. Perineuronal nets in the lateral hypothalamus area regulate cue-induced
673 reinstatement of cocaine-seeking behavior. *Neuropsychopharmacology* 2019; **44**(5): 850-858.
- 674
- 675 59. Guarque-Chabrera J, Sanchez-Hernandez A, Ibanez-Marin P, Melchor-Eixea I, Miquel M. Role of
676 Perineuronal nets in the cerebellar cortex in cocaine-induced conditioned preference, extinction,
677 and reinstatement. *Neuropharmacology* 2022; **218**: 109210.
- 678
- 679 60. Vazquez-Sanroman D, Leto K, Cerezo-Garcia M, Carbo-Gas M, Sanchis-Segura C, Carulli D *et al.*
680 The cerebellum on cocaine: plasticity and metaplasticity. *Addict Biol* 2015; **20**(5): 941-955.
- 681
- 682 61. Kalb RG, Hockfield S. Molecular evidence for early activity-dependent development of hamster
683 motor neurons. *J Neurosci* 1988; **8**(7): 2350-2360.
- 684
- 685 62. Sugiyama S, Di Nardo AA, Aizawa S, Matsuo I, Volovitch M, Prochiantz A *et al.* Experience-
686 dependent transfer of Otx2 homeoprotein into the visual cortex activates postnatal plasticity. *Cell*
687 2008; **134**(3): 508-520.
- 688
- 689 63. Frischknecht R, Gundelfinger ED. The brain's extracellular matrix and its role in synaptic plasticity.
690 *Adv Exp Med Biol* 2012; **970**: 153-171.
- 691
- 692 64. Dityatev A, Schachner M, Sonderegger P. The dual role of the extracellular matrix in synaptic
693 plasticity and homeostasis. *Nat Rev Neurosci* 2010; **11**(11): 735-746.
- 694
- 695 65. Gundelfinger ED, Frischknecht R, Choquet D, Heine M. Converting juvenile into adult plasticity: a
696 role for the brain's extracellular matrix. *Eur J Neurosci* 2010; **31**(12): 2156-2165.
- 697
- 698 66. Cabungcal JH, Steullet P, Morishita H, Kraftsik R, Cuenod M, Hensch TK *et al.* Perineuronal nets
699 protect fast-spiking interneurons against oxidative stress. *Proc Natl Acad Sci U S A* 2013; **110**(22):
700 9130-9135.
- 701
- 702 67. Morawski M, Bruckner MK, Riederer P, Bruckner G, Arendt T. Perineuronal nets potentially
703 protect against oxidative stress. *Exp Neurol* 2004; **188**(2): 309-315.
- 704
- 705 68. Trifilieff P, Martinez D. Imaging addiction: D2 receptors and dopamine signaling in the striatum as
706 biomarkers for impulsivity. *Neuropharmacology* 2014; **76 Pt B**(0 0): 498-509.
- 707

Valeri et al

- 708 69. Li JN, Liu XL, Li L. Prefrontal GABA and glutamate levels correlate with impulsivity and cognitive
709 function of prescription opioid addicts: A (1) H-magnetic resonance spectroscopy study.
710 *Psychiatry Clin Neurosci* 2020; **74**(1): 77-83.
- 711
- 712 70. D'Souza MS, Markou A. The "stop" and "go" of nicotine dependence: role of GABA and glutamate.
713 *Cold Spring Harb Perspect Med* 2013; **3**(6).
- 714
- 715 71. Balmer TS. Perineuronal Nets Enhance the Excitability of Fast-Spiking Neurons. *eNeuro* 2016; **3**(4).
- 716
- 717 72. Steullet P, Cabungcal JH, Bukhari SA, Ardelt MI, Pantazopoulos H, Hamati F *et al*. The thalamic
718 reticular nucleus in schizophrenia and bipolar disorder: role of parvalbumin-expressing neuron
719 networks and oxidative stress. *Mol Psychiatry* 2017.
- 720
- 721 73. Pantazopoulos H, Woo T-UW, Lim MP, Lange N, Berretta S. Extracellular Matrix-Glial
722 Abnormalities in the Amygdala and Entorhinal Cortex of Subjects Diagnosed With Schizophrenia.
723 *Arch Gen Psychiatry* 2010; **67**(2): 155-166.
- 724
- 725 74. Pantazopoulos H, Lange N, Hassinger L, Berretta S. Subpopulations of neurons expressing
726 parvalbumin in the human amygdala. *The Journal of comparative neurology* 2006; **496**(5): 706-
727 722.
- 728
- 729 75. Espinoza C, Guzman SJ, Zhang X, Jonas P. Parvalbumin+ interneurons obey unique connectivity
730 rules and establish a powerful lateral-inhibition microcircuit in dentate gyrus. *Nature*
731 *Communications* 2018; **9**(1): 4605.
- 732
- 733 76. Udakis M, Pedrosa V, Chamberlain SEL, Clopath C, Mellor JR. Interneuron-specific plasticity at
734 parvalbumin and somatostatin inhibitory synapses onto CA1 pyramidal neurons shapes
735 hippocampal output. *Nature Communications* 2020; **11**(1): 4395.
- 736
- 737 77. Yamada J, Ohgomori T, Jinno S. Perineuronal nets affect parvalbumin expression in GABAergic
738 neurons of the mouse hippocampus. *Eur J Neurosci* 2015; **41**(3): 368-378.
- 739
- 740 78. Lesnikova A, Casarotto PC, Fred SM, Voipio M, Winkel F, Steinzeig A *et al*. Chondroitinase and
741 Antidepressants Promote Plasticity by Releasing TRKB from Dephosphorylating Control of PTP σ in
742 Parvalbumin Neurons. *J Neurosci* 2021; **41**(5): 972-980.
- 743
- 744 79. Brown TE, Sorg BA. Net gain and loss: influence of natural rewards and drugs of abuse on
745 perineuronal nets. *Neuropsychopharmacology* 2023; **48**(1): 3-20.
- 746

Valeri et al

- 747 80. Huang YY, Kandel ER. D1/D5 receptor agonists induce a protein synthesis-dependent late
748 potentiation in the CA1 region of the hippocampus. *Proc Natl Acad Sci U S A* 1995; **92**(7): 2446-
749 2450.
- 750
- 751 81. Gasbarri A, Packard MG, Campana E, Pacitti C. Anterograde and retrograde tracing of projections
752 from the ventral tegmental area to the hippocampal formation in the rat. *Brain Res Bull* 1994;
753 **33**(4): 445-452.
- 754
- 755 82. Yin LT, Xie XY, Xue LY, Yang XR, Jia J, Zhang Y *et al*. Matrix Metalloproteinase-9 Overexpression
756 Regulates Hippocampal Synaptic Plasticity and Decreases Alcohol Consumption and Preference in
757 Mice. *Neurochem Res* 2020; **45**(8): 1902-1912.
- 758
- 759 83. Samochowiec A, Grzywacz A, Kaczmarek L, Bienkowski P, Samochowiec J, Mierzejewski P *et al*.
760 Functional polymorphism of matrix metalloproteinase-9 (MMP-9) gene in alcohol dependence:
761 family and case control study. *Brain Res* 2010; **1327**: 103-106.
- 762
- 763 84. Eichenbaum H. Prefrontal–hippocampal interactions in episodic memory. *Nature Reviews*
764 *Neuroscience* 2017; **18**(9): 547-558.
- 765
- 766 85. Goodman J, Packard MG. Memory Systems and the Addicted Brain. *Frontiers in Psychiatry* 2016;
767 **7**.
- 768
- 769 86. Markou A, Kosten TR, Koob GF. Neurobiological similarities in depression and drug dependence:
770 a self-medication hypothesis. *Neuropsychopharmacology* 1998; **18**(3): 135-174.
- 771
- 772 87. Gilman SE, Abraham HD. A longitudinal study of the order of onset of alcohol dependence and
773 major depression. *Drug Alcohol Depend* 2001; **63**(3): 277-286.
- 774
- 775 88. Young MA, Fogg LF, Scheftner WA, Fawcett JA. Interactions of risk factors in predicting suicide.
776 *Am J Psychiatry* 1994; **151**(3): 434-435.
- 777
- 778 89. Roughley PJ, Mort JS. The role of aggrecan in normal and osteoarthritic cartilage. *Journal of*
779 *Experimental Orthopaedics* 2014; **1**(1): 8.
- 780
- 781 90. Riga D, Kramvis I, Koskinen MK, van Bokhoven P, van der Harst JE, Heistek TS *et al*. Hippocampal
782 extracellular matrix alterations contribute to cognitive impairment associated with a chronic
783 depressive-like state in rats. *Sci Transl Med* 2017; **9**(421).
- 784
- 785 91. Blanco I, Conant K. Extracellular matrix remodeling with stress and depression: Studies in human,
786 rodent and zebrafish models. *Eur J Neurosci* 2021; **53**(12): 3879-3888.
- 787

Valeri et al

- 788 92. Sun ZY, Bozzelli PL, Caccavano A, Allen M, Balmuth J, Vicini S *et al*. Disruption of perineuronal nets
789 increases the frequency of sharp wave ripple events. *Hippocampus* 2018; **28**(1): 42-52.
- 790
- 791 93. Karst H, Joëls M. Corticosterone Slowly Enhances Miniature Excitatory Postsynaptic Current
792 Amplitude in Mice CA1 Hippocampal Cells. *Journal of Neurophysiology* 2005; **94**(5): 3479-3486.
- 793
- 794 94. Duric V, Banasr M, Stockmeier CA, Simen AA, Newton SS, Overholser JC *et al*. Altered expression
795 of synapse and glutamate related genes in post-mortem hippocampus of depressed subjects. *Int*
796 *J Neuropsychopharmacol* 2013; **16**(1): 69-82.
- 797
- 798 95. Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in
799 depression: recent advances and novel treatments. *Neuropsychiatr Dis Treat* 2019; **15**: 1249-
800 1258.
- 801
- 802 96. Miguel-Hidalgo JJ. Astrocytes as Context for the Involvement of Myelin and Nodes of Ranvier in
803 the Pathophysiology of Depression and Stress-Related Disorders. *J Psychiatr Brain Sci* 2023; **8**.
- 804
- 805 97. Kohler-Forsberg O, C NL, Hjorthoj C, Nordentoft M, Mors O, Benros ME. Efficacy of anti-
806 inflammatory treatment on major depressive disorder or depressive symptoms: meta-analysis of
807 clinical trials. *Acta psychiatrica Scandinavica* 2019; **139**(5): 404-419.
- 808
- 809 98. Fries GR, Saldana VA, Finnstein J, Rein T. Molecular pathways of major depressive disorder
810 converge on the synapse. *Mol Psychiatry* 2023; **28**(1): 284-297.
- 811
- 812 99. Mahajan GJ, Vallender EJ, Garrett MR, Challagundla L, Overholser JC, Jurjus G *et al*. Altered neuro-
813 inflammatory gene expression in hippocampus in major depressive disorder. *Prog*
814 *Neuropsychopharmacol Biol Psychiatry* 2018; **82**: 177-186.
- 815
- 816 100. Scarlett JM, Hu SJ, Alonge KM. The "Loss" of Perineuronal Nets in Alzheimer's Disease: Missing or
817 Hiding in Plain Sight? *Front Integr Neurosci* 2022; **16**: 896400.
- 818
- 819
- 820
- 821
- 822
- 823

Valeri et al

874

Cohort A: Human subjects for SUD, SUD/MDD, and MDD analyses				
	SUD n=20	SUD/MDD n=24	MDD n=20	Control n=20
Age, Years	34.8±9.0	43.9±11.1	47±11.4	43.2±11.42
Sex				
Male	17	16	14	13
Female	3	8	6	7
Race				
White	13	20	17	11
Black	7	4	3	9
Brain pH	6.57±0.23	6.54±0.27	6.5±0.32	6.5±0.25
PMI, Hours	18.58±8.5	20.2±7.6	23.7±5.9	21.2±6.8
Cohort B: PFA fixed samples from control subjects for labeling of synaptic markers and PVB neurons				
Age	43.0±25.2			
Sex	2 Male, 1 Female			
Hemisphere	2 Right, 1 Left			
Cohort C: Rhesus macaque subjects				
	Alcohol drinkers n=7	Control n=5		
Age, Years	7.20±0.04	6.90±0.49		
Sex	Male (n=7)	Male (n=5)		
BAC, mg pct	101.46±12.76	NA		


840

841 **Table 1.** Basic cohort demographic information for both human and rhesus macaque subjects.
 842 Abbreviations: SUD, substance use disorder; MDD, major depressive disorder; PFA:
 843 Paraformaldehyde; PMI, postmortem interval, BAC, blood alcohol concentration, 12-month
 844 average. Values represent mean ± SEM.

845

846

Valeri et al



847


848 **Figure 1. Altered PNNs in SUD and MDD.** (A and B) Representative low-magnification
 849 photomicrographs of CA1 SO PNNs labeled by WFA, scalebars = 0.5 mm. (C and D) High-
 850 magnification photomicrographs of WFA-labeled CA1 SO PNNs, scalebars = 50 μm. (E)
 851 Diagnostic group comparisons of PNN densities in CA1 stratum oriens. Subjects with SUD had
 852 significantly increased densities of PNNs ($p < 0.007$; adjusted for significant effects of cocaine
 853 history and PMI) whereas subjects with MDD displayed significantly reduced PNN densities ($p <$
 854 0.05 ; adjusted for significant effects of sex and calcium channel blockers). No significant effects
 855 were found in the comorbid SUD and MDD group. (F) Diagnostic group comparisons of
 856 normalized hippocampal *Pvb* gene expression, with a gradient increase between SUD ($p < 0.007$;
 857 adjusted for significant effects of cocaine in the toxicology report), SUD/MDD ($p < 0.008$;
 858 adjusted for significant effects of MDD duration), and MDD ($p < 0.005$). (G) Representative PNN
 859 quantification overlays of hippocampi from subjects within diagnostic groups. (H and I)
 860 Representative low-magnification photomicrographs of CA4 WFA-labeled glia, scalebars = 0.5
 861 mm. (J and K) Representative high-magnification WFA-labeled glia, scalebars = 80 50 μm. (L)
 862 Numerical density measurements of CA4 WFA-labeled glial cells in subjects with SUD, MDD, and
 863 SUD/MDD. (M) Normalized gene expression of *Gfap* was significantly decreased in subjects with
 864 comorbid SUD and MDD ($p < 0.02$; adjusted for significant effects of antidepressant history), but
 865 unaffected in either isolated disorder. (N) Representative WFA⁺ glia quantification overlays of
 866 hippocampi from subjects within diagnostic groups. Error bars are mean ± SEM.

867

868

869

Valeri et al




870

871 **Figure 2.** Gene expression of the *excitatory synaptic marker Vamp2* is altered in SUD and MDD.
 872 (A) Gene expression of the presynaptic vesicle marker *Vamp2* is increased in both SUD and
 873 MDD, but not in the comorbid condition. (B-E) Multiplex immunofluorescent imaging of VAMP2
 874 immunoreactive puncta within a PNN and on the surface of a PVB interneuron. (B) WFA-labeled
 875 PNN (green), (C) PVB interneuron (blue) and VAMP2 synaptic puncta (red) and spatial overlap
 876 (yellow) (arrows indicate overlap). (D) Composite z-projection of WFA, PVB, and VAMP2. (E)
 877 Zoomed inset of 1D, with arrows denoting spatial overlap of VAMP2 with WFA (yellow puncta).
 878 (F) There were no significant changes in transcription of the synaptic marker *Syn1* in any of the
 879 diagnostic groups. (G-J) Multiplex immunofluorescent imaging depicting SYN1 labeling within a
 880 PNN surrounding a PVB interneuron. (G) WFA-labeled PNN (green), (H) PVB neuron (blue) and
 881 SYN1 (red), (I) composite z-projection of all three channels. (J) Zoomed inset depicts spatial
 882 overlap with of SYN1 puncta with WFA labeling (arrows to yellow puncta). All scalebars are 10
 883 μ m. Error bars are mean \pm SEM.

884

Valeri et al




885

886 **Figure 3.** Gene expression of ECM biosynthetic and regulatory molecules in SUD and MDD. (A)
887 Gene expression of the ECM proteolytic molecule *Mmp9* was significantly decreased in subjects
888 with SUD compared to controls ($p < 0.05$), but no significant differences were detected in the
889 other two diagnostic groups. (B) Analysis of covariance uncovered significantly decreased mRNA
890 levels of cathepsin S in subjects with SUD ($p < 0.03$; adjusted for significant effects of cocaine in
891 the toxicology report). Subjects with MDD had significantly increased expression of cathepsin S
892 compared to controls ($p < 0.03$; adjusted for significant effects of alcohol history and ZT time of
893 death). (C) Gene expression of the CSPG aggrecan was significantly increased in subjects with
894 comorbid SUD and MDD ($p < 0.03$) but was unaffected in either condition separately. (D) Gene
895 expression of the CSPG biosynthetic molecule *Chsy1* was significantly increased in subjects with
896 SUD ($p < 0.05$; adjusted for significant effects of tissue pH) and in subjects with comorbid SUD
897 and MDD ($p < 0.0001$; adjusted for significant effects of tissue pH and duration of AUD), while
898 patients with MDD did not meet significance in any direction. Error bars are mean \pm SEM.

899

Valeri et al



900

901 **Figure 4.** Chronic alcohol self-administration increases PNN densities throughout the
 902 hippocampus of rhesus monkeys. Abbreviations: DG GCL, granule cell layer of the dentate gyrus;
 903 SLM, stratum lacunosum moleculare; SGZ, subgranular zone; CA, cornu ammonis; SO, stratum
 904 oriens; SP, stratum pyramidale. (A) Representative microscopy of PNNs labeled with WFA in CA1
 905 SO, scalebar = 50 μm. (B) Inset of Figure 4A at high-magnification, scalebar = 30 μm. (C)
 906 Representative microscopy of a WFA-labeled glial cell proximal to the DG GCL, scalebar = 50
 907 μm. (D) Inset of Figure 4C at 40× magnification, scalebar = 50 μm. (E) Comparisons of PNN
 908 densities throughout the hippocampus between control (white bars) and monkeys with chronic
 909 alcohol self-administration (red bars). (F) Comparison of WFA-glia densities in the DG GCL and
 910 DG SLM between control and monkeys with chronic alcohol self-administration. (G) Comparison
 911 of WFA-glia densities in the SGZ and CA nuclei of the hippocampus between control and monkeys
 912 with chronic alcohol self-administration.

913


914

915

916

917

Valeri et al



918

919 **Figure 5.** Summary diagram of proposed ECM and synaptic alterations in the hippocampus of
920 subjects with SUD with or without comorbid MDD. Panels providing visual depictions of
921 pathological observations from the present study. Numbers of arrows describe the intensity of
922 changes compared to the other diagnostic groups, and a key is provided within the control panel
923 to characterize the graphics used within the figure. Created with BioRender.com.

924

925